A breakthrough in the treatment of multiple sclerosis (MS), a condition where the immune system attacks the central nervous system, may have been found. Stem cell transplantation from one’s blood and a high-dose of immunosuppressive therapy has proven to be working.
In a span of five years, 69% of trial patients who have undergone the treatment of being administered high doses of immunosuppressive therapy, and then carrying out cell transplantation (HDIT/HCT), have survived. No relapse or associated symptoms of the condition have been seen.
National Institute of Allergy and Infectious Disease (NIAID) was backing the trial. Immune Tolerance Network (ITN), was then responsible for carrying out the HALT-MS trial, and Dr. Richard Nash of Colorado Blood Cancer Institute, was its principal investigator. The final results of the five-year study were posted in Neurology, which is a medical journal, on Feb 1, 2017. HDIT/HCT treatment has proven to be far much effective than other forms of MS medication according to the findings.
Patients with MS who don’t respond to other existing forms of medication may undergo HDIT/HCT. The therapy has brought about a long-term solution in the treatment of MS. HDIT/HCT is still under investigation to establish its benefits and risks.
About Dr. Shiva
Dr. Shiva Vasishta graduated from Government Medical College Nagpur in 1979. He also attended Boston University Medical Centre as well as Tufts Medical Centre. Dr. Shiva Vasishta is licensed by the American Board of Psychiatry and Neurology as a Neurologist. He has practiced for 38 years, and currently practicing in Voorhees, New Jersey. Dr. Shiva Vasishta is a member of Eastern Neurodiagnostic Association Pc and is affiliated with Kennedy University Hospital. Dr. Shiva Vasishta communicates in both English and Spanish.